Analyst recommendations

The biotechnology sector has been incredibly successful in 2014 year. Its growth outperformed the growth of S&P 500  stunning 36%. Analysts at JP Morgan believe that a huge priority sector dynamics can decrease in 2015 year, but may remain the same level. The main drivers the success of biotech in 2014 were a high demand for the main products of the sector, the positive results of many clinical studies phase a wave of successful initial public offerings.
Date Company Who recommends Recommendation Target price
Vertex Pharmaceuticals Incorporated Argus Buy 155
Amgen Inc. Deutsche Bank Buy 180
Anthem, Inc. RBC Capital Mkts Buy 198
Universal Health Services Inc. Barclays Buy 150
Allergan plc Deutsche Bank Buy 342
Boston Scientific Corporation Deutsche Bank Buy 22
HCA Holdings, Inc. UBS Buy 90
Pfizer Inc. Morgan Stanley Buy 43
AbbVie Inc. UBS Buy 78
Biogen Inc. Bernstein Buy 360
Gilead Sciences Inc. Deutsche Bank Buy 124
Bristol-Myers Squibb Company Morgan Stanley Buy 80
DENTSPLY International Inc. Morgan Stanley Buy 70
Edwards Lifesciences Corp. RBC Capital Mkts Buy 160
Merck & Co. Inc. UBS Buy 68
St. Jude Medical Inc. Deutsche Bank Buy 77
Stryker Corporation Argus Buy 120
Mallinckrodt Public Limited Company Barclays Buy 80
Abbott Laboratories Barclays Buy 52
DaVita HealthCare Partners Inc. RBC Capital Mkts Buy 83
1 2